News | Cardiac Diagnostics | February 22, 2016

Statins May Lower Heart Disease Risk in People with Sleep Apnea

Study finds drugs protect blood vessels from substances that cause inflammation

statins, sleep apnea, heart disease risk, CUMC study, Science Translational Medicine

February 22, 2016 — A new study conducted at Columbia University Medical Center (CUMC) has revealed some of the underlying mechanisms that may increase the risk of heart disease in people with sleep apnea. The study also found that statins — the cholesterol-lowering medications commonly prescribed to combat heart disease — may help reverse this process.

The study was published in the January 6th online edition of Science Translational Medicine.

More than 18 million adults have obstructive sleep apnea, in which relaxation of muscles in the throat during sleep causes frequent interruptions in breathing. The condition disrupts sleep and causes fluctuations in oxygen levels, which can lead to excessive daytime sleepiness and difficulty concentrating. In addition, sleep apnea triples the risk for developing heart disease, including hypertension and ischemic stroke.

“It has been well documented that sleep apnea is a powerful and independent risk factor for heart disease, but the underlying reason for this has remained unclear,” said Sanja Jelic, M.D., associate professor of medicine at CUMC. “The aim of our study was to understand the mechanisms by which sleep apnea may lead to heart disease in an effort to reduce the risk.”

The study included 128 people who underwent sleep studies at CUMC’s Sleep Disorders Center, including 76 people who were diagnosed with obstructive sleep apnea and 52 people who did not meet the criteria for this condition. The researchers analyzed cells that line blood vessel walls (obtained from the participants’ arm veins) to look for differences that may explain the increased risk for heart disease in people with sleep apnea.

The investigators found that people with sleep apnea had higher levels of a protein called CD59, which inhibits the buildup of inflammatory proteins on cell surfaces.

Unexpectedly, however, CD59 was found mainly within the cells of those with sleep apnea, instead of on the cell surface. As a result, the cells of the sleep apnea group had larger deposits of inflammatory proteins.

“This unexpected finding suggests that repeatedly interrupting oxygen flow during sleep draws CD59 away from the cell surface, where it is better positioned to do its job in protecting cells from inflammation,” said Jelic.

The researchers also noticed that CD59 was preserved on the cell surface in a small subset of subjects with sleep apnea who were being treated with statins, similar to those who did not have sleep apnea. Further testing revealed that cholesterol draws CD59 away from the cell surface in a process known as endocytosis.

“We were surprised to discover that these commonly prescribed drugs appeared to reverse the process that leads to vascular injury, and ultimately heart disease, in people with sleep apnea,” said Jelic. “This striking result provides support for the concept that statins may be considered as a primary prevention strategy for reducing heart disease risk in people with sleep apnea, pending further clinical trials.”

The paper is titled, “Increased Internalization of Complement Inhibitor CD59 May Contribute to Endothelial Inflammation in Obstructive Sleep Apnea.”

The study was supported by a grant from the NIH/National Heart, Lung, and Blood Institute (R01HL106041). The researchers declare no financial or other conflicts of interest.

For more information: www.stm.sciencemag.org

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init